Sept 30 (Reuters) - IMV Inc IMV.TO :
* PRELIMINARY RESULTS FROM IMV'S PHASE 2 BASKET TRIAL EVALUATING DPX-SURVIVAC AS A COMBINATION THERAPY IN PATIENTS WITH ADVANCED AND METASTATIC SOLID TUMORS TO BE PRESENTED AT ESMO CONGRESS 2019
* TREATMENT WELL-TOLERATED, WITH NO RELATED GRADE 3-4 OR IMMUNE-RELATED ADVERSE EVENTS